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Administration of 98% ethanol destroys tissues by coagulative necrosis. In the rat bearing 1,2-
dimethylhydrazine-induced colonic carcinoma which has spread to the liver, direct injection of 0.1-0.2
ml ethanol into each of the hepatic metastases at the time of total colectomy afforded a significant
survival advantage relative to colectomy alone (20.1 + 0.2 vs 12.8 + 0.2 months of age, mean _+ SEM,
n 20, p < 0.01 by the Mann-Whitney U test). A pilot study was, therefore, carried out (2 women and
4 men, age range 43 to 71 years mean 56) to examine the clinical significance of these observations in
patients with multiple hepatic metastases from carcinoma of the sigmoid colon. The tumour was
resected then all palpable hepatic secondaries were injected with 1-1.5 ml of 98% ethanol. Two weeks
post-operatively and thereafter once every two months any hepatic lesions detected ultrasonically were
similarly treated percutaneously. All the patients tolerated this treatment without any observed distress
or adverse effects. Their mean survival measured from the time of tumour resection until death from any
cause was 20 months (range 17 to 26 months). The survival gain afforded by chemonecrosis in addition
to its simplicity and safety deserves further consideration to assess the exact role of this method in the
treatment of liver metastases from colonic cancer.
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INTRODUCTION
Carcinoma of the large bowel is the second leading cause of death from cancer in
Western industrial countries. The most important prognostic factor for long-term
survival of patients is the extent of tumour at the time of diagnosis. The high
incidence and mortality rates of colonic cancer stress the need for improved
therapeutic modalities that can combat this disease more effectively.
Liver metastases are present on initial diagnosis of large bowel cancer in 25 to
30% of patients1-3. Even after curative resection of the primary colorectal tumour
between 40 and 60% of patients will develop recurrence and about 20 to 25% of
them will have only liver metastases3’4. Once hepatic secondaries have developed,
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the prognosis is poor, with an expected median survival time of only a few months.
A review from the Mayo clinic showed that 20% of patients with solitary liver
metastases from colorectal cancer survived more than 3 years without treatment4’.
In another study, patients with synchronous solitary metastases of colorectal cancer
had a 3-year survival rate of 17% compared to 1% for patients with multiple
metastases6. It is possible that since the stage of the disease affects the outcome,
early detection improves survival. Although isolated metastases exclusively con-
fined to the liver are infrequent, a loco-regional treatment has the best chance of an
effective palliation or even cure when applied to patients with metastatic spread
confined to the liver. Liver resection is the only treatment which has the potential
to cure a patient with liver tumours, however there seems to be an agreement to
exclude patients with 4 or more metastases, extrahepatic disease, more than 50%
hepatic replacement by tumour and lesions that cannot be resected with at least a
margin of 10 mm7. Regrettably, the number of patients who fulfill these qualifica-
tions is limited and only a small number will readily benefit from liver resection7.
Chemotherapy of liver tumours has evolved from systemic to intra-arterial
treatment with single drug to multiple drug combinations and to the innovative
approach with delivery systems like the implantable pump for continuous administ-
ration of the treatment. The most consistently used chemotherapeutic drug has
been 5-FU. Systemic administration of this agent for the treatment of liver
metastases from colorectal cancer induces an objective response in between 15 and
25% of patients yet no significant survival gain has been reported8. On the other
hand, higher response was noted when chemotherapeutic medicines, particularly
fluorodeoxyuridine, were infused intra-arterially into the liver9’. It is rather
disheartening to note that complications such as chemical hepatitis, gastritis,
duodenitis, cholecystitis, thrombosis of the arterial or venous line, and biliary
sclerosis are not uncommon and lead to the cessation of treatment. Until chemoth-
erapeutic regimens can be developed that significantly improve the survival of
patients with advanced colonic cancer and can be expected to cause objective
tumour shrinkage in at least half of the patients being treated, the use of these
drugs can only afford limited gains.
Interruption of the hepatic arterial circulation by simple ligation of the hepatic
artery, ligation with permanent or intermittent dearterialization and embolization
with non-degradable or degradable material have all been clinically employed to
produce necrosis of hepatic metastases from colorectal cancer. These procedures
are not specifically directed at the metastases and may produce such complications
as liver abscesses, liver failure, haemorrhage and septicaemia. Moreover, although
considerable tumour regression may occur after hepatic artery ligation and com-
plete dearterialization, survival seems not to significantly increase. This was
thought to be due to survival of neoplastic cells on the tumours’ rim. Consequently,
arterial interruption was combined with infusion of cytotoxic agents to attack the
surviving fraction on the rim2. However, the complication rate was rather high12.
Repeated intermittent dearterialization in an attempt to confine damage to the liver
metastases and to reduce injury to normal hepatic tissue while combating the
tendency for arterial collateral formation may overcome some of the limitations of
current methods of interrupting the hepatic arterial circulation3.
Other modalities for the treatment of hepatic metastases are also available, but
they all have limitations. The efficacy of regional or total body hyperthermia
depends on tumour size and variations in blood flow which have a major influenceALCOHOL-INDUCED CHEMONELROSIS 35
on heat dissipation and precludes its uniform delivery. Techniques employing
ultrasound and microwave heating are more commonly used but are mainly
restricted to superficial tumours4. Devitalization of hepatic tumours by cryother-
apy imposes the difficulty of adjusting the volume of frozen tissue and restricting it
to the tumour1S. Furthermore, the frozen mass per unit time is a function of
freezing duration and blood supply so that a considerable time may be needed
depending on the size and blood flow of a particular tumour to achieve a complete
freezing15.
It is consequently construed that efforts should not be spared in the search for an
effective and simple yet safe method which enables localized destruction of hepatic
metastases without any significant damage to the surrounding normal paranchyma
or to the rest of the body’s tissues and organs. On the basis of the fact that new
hepatic metastases continue to appear, it is necessary to have a dynamic therapeutic
system which could be repeatedly applied without any significant inconvenience or
risks and this is perhaps the real challenge.
Injection of ethyl alcohol in high concentrations into tissues produces coagulative
necrosis16. This communication reports the experimental and clinical results of
injecting hepatic metastases from colonic carcinoma with alcohol.
METHODS AND RESULTS
The benefits of direct injection of 98% ethanol (BDH Chemicals, Poole, UK) into
hepatic metastases from 1,2-dimethylhydrazine (DMH)-induced colonic cancer was
investigated in the Sprague-Dawley rat. At 10 weeks of age, rats were subcuta-
neously injected every week with 10 mg/kg DMH for 28 weeks. They were then
housed for 3 months. At the end of this period, it was noticed that all the animals
had developed colonic carcinoma with multiple hepatic metastases. These lesions
occurred in both lobes of the liver and ranged between 5 and 12 tumours per animal
(mean 7). Total colectomy and the fashioning of an ileostomy coupled with direct
injection of 0.1 0.2 ml of ethanol into each of the hepatic metastases, after
mobilizing the liver by dividing its fascial attachments to facilitate easier tumour
detection by inspection and palpation, afforded a significant survival advantage
relative to colectomy alone (20.1 + 0.2 months of age, vs 12.8 + 0.2 months of
age, mean + SEM, n 20, p < 0.01 by the Mann-Whitney U Test). At autopsy,
all the control animals demonstrated marked increase in the size and number of
their hepatic lesions, which appear to have been the cause of death rather than
extra hepatic tumour spread. The latter spread was observed in only 3 of these
animals. Conversely, all the rats in the ethanol treatment group developed extra
hepatic metastases, particularly in the lungs, and had liver lesions not different in
number, size or pattern of distribution to those noted at the time of the injections.
The impression thus gathered is that these animals had probably died from disease
spread beyond the liver.
The clinical implications of these observations were, therefore, examined in a
pilot study carried out at the Medical City in Iraq on six patients (2 women and 4
men with an age range of 43 to 71 years, mean 56) who had adenocarcinoma of the
sigmoid colon with multiple hepatic secondaries. The study was approved by the
Ethical Committee on Human Experimentation and every patient gave written
informed consent. Exclusion criteria were as follows: age over 80 years; risk factors36 A.S. SALIM
(previous colonic cancer or adenomatous polyp(s), familial polyposis, ulcerative
colitis, Crohn’s disease); emergency admission or fever, septicaemia, or peritonitis
on presentation; jaundice; ascites; leg oedema; liver metastases not readily pal-
pable at laparotomy or fewer than 5 hepatic metastases; presence of extrahepatic
metastases (pulmonary); pregnancy; alcoholism; taking any form of regular medi-
cation; hypertension; diabetes; serious underlying diseases; previous gastrointesti-
nal surgery; history of radiotherapy, chemotherapy or any malignancy; undifferen-
tiated carcinoma; synchronous carcinomas; or invasion of the abdominal wall or
adjacent structures found during laparotomy. Sigmoid carcinoma was diagnosed by
endoscopy with biopsies and double contrast barium enema. The liver was
examined by ultrasound and carcinoembryonic antigen (CEA) levels were deter-
mined (upper limit of normal 25/g/L). The bowel was prepared by a morning and
an evening sodium picosulphate sachet on the day preceding surgery. At induction
of anaesthesia, all patients were given 500 mg of ampicillin, 80 mg of gentamicin
and 500 mg of metronidazole. Following exploration of the abdominal cavity, any
palpable lymph nodes at the porta hepatis were excised for histologic examination
and all the palpable hepatic metastases were biopsied using a Tru-cut needle. The
colonic tumour was resected and an end to end anastomosis effected, then all the
palpable hepatic metastases were slowly injected under direct vision with 1-1.5 ml
of 98% ethanol using a 22 gauge needle. The fascial attachments of the liver were
divided as deemed necessary to facilitate exposure. The number of the hepatic
secondaries ranged from 5 to 14 with a mean of 9 and occurred in both lobes of the
liver. Two of the patients studied had carcinoma in their porta hepatis lymph
nodes. No blood transfusions were administered to any patient.
All the patients made an uneventful recovery from surgery apart from one
patient who developed a wound infection. None of the patients experienced any
significant discomfort or pains that could be attributed to the ethanol injections.
Moreover, these injections caused no pyrexia or abnormal liver reactions reflected
in the liver function tests (only marginal elevation of the aminotransferases was
noted in the immediate postoperative period). The liver ultrasound scan was
repeated two weeks following surgery to detect and inject any residual hepatic
metastases. These lesions were found in every patient, were not more than two in
number, and were injected percutaneously under ultrasound control using a long 22
gauge needle (Cook Inc., Bloomington, Indiana, USA) the skin port of entry
was anaesthetized with 1% plain xylocaine and delivering 1- 1.5 ml of ethanol
into each lesion. Ultrasonography enabled the completeness of tumour destruction
to be assessed. At this stage it was noted that the serum alkaline phosphatase
(normal range" 40-120 iu/L) and CEA levels were significantly (p < 0.001 by the
Mann-Whitney U test) lower than their corresponding preoperative levels (93 iu/L
+ 4.1 vs 211 iu/L + 3.7 and 26.1/g/L + 1.3 vs 81.3/g/L + 4.8, mean + SEM).
All the patients were then reviewed every two months as out-patients when
sigmoidoscopy (60 cm flexible) with biopsies of any suspicious colorectal mucosa,
full blood counts, liver function tests, CEA levels, faecal testing for occult blood
and a liver ultrasound scan with percutaneous injection of any obvious or suspicious
lesions were carried out for the rest of the patients’ lives. During each of these
reviews, at least one and no more than three hepatic lesions were detected and
treated in every patient. No obvious adverse effects caused by the ethanol
injections were noted in any patient and all were observed to enjoy a good quality
life. None of the patients died during the first postoperative year. Death was due toALCOHOL-INDUCED CHEMONELROSIS 37
disease spread in all the patients. The mean survival measured from the time of
tumour resection until death from any cause was 20 months (range 17 to 26
months).
DISCUSSION
Patients with malignancies that have metastasised to the liver have a poor
prognosis. In the presence of untreated synchronous hepatic metastases from
colorectal carcinoma, the survival time can be as short as a few months. While in
some of these patients surgical excision of the hepatic lesions can afford long-term
survival4’5’7, results with other therapeutic measures have been disappointing in this
respect.
It has been reported that approximately one-fourth of the patients bearing liver
metastases from colorectal cancer have hepatic tumours that can be resected, but
only 25% of these patients will live 5 years or more after such tumours have been
removed. On the other hand, the incidence of recurrence in the liver alone
following resection of hepatic metastases varies from 5 to 28% 4. This recurrence is
largely determined by the following: involved or narrow resective margins, bilater-
ality of resected lesions and the number of hepatic metastases (< 4) removed. Since
it is not ethical to deny patients treatment of proven value, the natural history of
untreated cancer cannot be considered the standard against which the effectiveness
of any treatment is measured. Within this context retrospective analyses based on
historical controls are confusing and unreliable. Consequently, resective treatment
being the most effective therapeutic weapon available against hepatic metastases
becomes the standard against which any new treatment for these lesions can be
tested.
The present study introduces chemonecrosis by alcohol as a new approach for
localized dynamic destruction of hepatic metastases from colonic cancer. The
results suggest that this approach offers a survival gain relative to other therapeutic
modalities such as continuous intra-arterial chemotherapy, temporary dearteriali-
zation, and repeated intermittent dearterialization. In addition, chemonecrosis
avoids the operative mortality of resectional surgery and also avoids its limitations
be they tumour-related or operative risk-related. These advantages over resective
treatment may be even more appreciated when the latter treatment is used only for
palliation, because metastatic lesions in the liver cause pain, or when the patient
may succumb from these lesions before being troubled by other sites of spread.
Under these circumstances and even in the presence of other indicators of poor
prognosis, the additive effect of palliation is a reasonable goal particularly if
therapeutic success is to be interpreted in terms of the quality and comfort of the
remaining part of a patient’s life and not only the duration of this life. Although it
has been reported
4 that in patients who had major hepatic resections the period of
life without symptoms closely paralleled length of life so that patients were not
made to live longer only to suffer more, chemonecrosis can avoid altogether the
time and discomfort involved in major surgery in addition to being feasible in those
patients considered a poor anaesthetic or surgical risk.
One of the most important points to note about chemonecrosis is that it requires
no special devices or systems to be installed during surgery and can be applied
whenever hepatic secondaries are noted. The advantage of this point can be readily38 A.S. SALIM
realized when one recalls the proportion of colorectal cancer cases that do not
appear to have metastasised to the liver, yet soon after their resection hepatic
secondaries become obvious. Whether this last effect is produced by manipulations
of the primary lesion, or represents metastases reaching the liver from affected
lymphatics, or growth of metastases already present in the liver at the time of
surgery to a size which allows detection, it can be effectively dealt with by
percutaneous chemonecrosis. The dynamicity of this approach also means that any
lesions which were missed can be treated the following session. In connection with
this point the tremendous regenerative power of the liver enables these sessions to
be repeated without any fear of serious consequences. In patients with colorectal
cancer, exact diagnosis of the presence or absence of liver metastases is not always
easy. Although it is not necessary to destroy all the hepatic secondaries during
surgery for the primary lesion and may indeed be undesirable in poor risk patients
or when it is thought unwise to increase operative time or extend the magnitude of
surgery and increase its impact on the patient, the improved detectability of liver
metastasis at the time of colorectal operation by the use of intraoperative ultraso-
nography overcomes the diagnostic limitations of percutaneous ultrasonography
and CT scanning by detecting preoperatively unknown or nonpalpable lesions
thereby helping operative decision making and providing a baseline for postopera-
tive chemonecrosis. Considering the fact that this method is relatively simple,
inexpensive and can be repeatedly applied without any apparent complications or
mortality, it deserves a more detailed analysis through randomized trials to
determine its exact place in the treatment of hepatic secondaries in comparison
with current treatment options.,
The possibility that removal of the primary tumour accelerates the growth of
micrometastases may explain the clinical observation that control of hepatic
metastases stimulates tumour growth at extrahepatic sites3. It can, however, be
argued that this control allows time for extra hepatic tumour sites to occur which
would not have otherwise been encountered due to the limited survival. Tumours
at these sites may be more readily detected by CT scanning and it is perhaps very
much worthwhile from a survival point of view to consider destroying them
percutaneously by chemonecrosis.
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COMMENTARY
Liver metastases are the main cause of death in patients with colorectal cancer. A
fact that is particularly relevant in the United States where over 150,000 people a
year develop colon cancer and over 60,000 die of it. Since the liver is the main site
of metastatic spread any remedy for liver metastases is needed and usually eagerly
adopted.
Dr Salim’s study is a report on a new method for treating liver metastases, the
direct injection of absolute alcohol into liver tumors. He reports on his laboratory
work as well as on a pilot study in 6 patients. In his laboratory study 20 rats were
placed into a treatment or control group. All animals had chemically induced colon
cancer and had multiple liver metastases. All animals were treated with a colec-
tomy. The treatment group also received multiple injections of ethanol into the
liver metastases. The rats in the control group without the injections died at 12.8
months while those with the ethanol died at 20.1 months. The control animals all
had increased liver metastases at death while the treatment group seemed to have
no progression in their liver metastases but had extrahepatic spread.
This laboratory experience seems very similar to the clinical effects that have
been seen in patients with hepatic metastases from colorectal primaries who are40 A.S. SALIM
treated with continuous hepatic artery infusions (CHAI) of floxuridine (FUDR).
Most of the studies on the FUDR infusions have shown increased hepatic control
with modest survival benefits 1’2, but eventual demise of the patients because of
extrahepatic disease. One additional fact known about FUDR infusions is the
objective response rate which in selected patients can be as high as 93%3. Dr Salim
did not tell us about the objective response in the rats so I would assume their was
no response but only stable disease.
From this limited success he went on to do a pilot study in 6 patients. The
patients all had primary colon cancers that had not yet been resected. All patients
underwent a colon resection and injection of hepatic metastases at the same
operation. Two weeks after surgery the patients had percutaneous injections of any
ultrasonographically apparent lesions. He mentioned that the CEA and alkaline
phosphatase went down after the operations. The significance of this is question-
able since all patients had their liver metastases. Over the ensuing months these
patients were followed and each time a liver metastases turned up it was treated
with percutaneous injections. The mean survival time for these 6 patients was 20
months (17-26 months).
Is this an exciting report? It is hard to say at this time. It seems that the 6 patients
who received the treatment had a prolonged survival with a mean survival of 20
months, but it is hard to know in select patients if this really means anything.
Certainly compared to no treatment it is an improvement. However, in a study I
carried out at the City of Hope when selected patients with multiple liver
metastases were treated with CHAI of FUDR by the implantable Infusaid pump
the mean survival was 19.8 months3. Furthermore 93% partial or complete hepatic
responses were seen in this group. As in the Iraqi study most patients died from
extra-hepatic disease.
Dr Salim’s study does not address response rates and it suggests that all the
patients had recurrent hepatic metastases. In the City of Hope study we did not see
recurrent hepatic disease. I certainly think that the ethanol injections have not yet
been shown to be superior to CHAI (even though Dr Salim suggests they are). This
does not mean it is not useful or interesting. One aspect that seems appealing is the
apparent low toxicity. Also ethanol injections would be easy to perform in most
hospital settings at a reasonable cost.
Perhaps CHAI or FUDR and ethanol injections can be combined to increase
response and increase hepatic control. Certainly an approach such as the ethanol
injections might and should be compared to infusion alone in a controlled study.
New modalities such as ethanol injections may not be the cure we are all looking
for but in conjunction with other already adopted modalities we may be able to
begin to accomplish the complete and durable responses toward which we are all
working.
M. Margaret Kemeny, M.D.F.A.C.S.
Chief, Surgical Oncology
Associate Professor of Surgery
New York Medical CollegeALCOHOL-INDUCED CHEMONELROSIS 41
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